Drug Product Development and Manufacturing

Despite the rise of biologics, gene therapies, and cell-based medicines, small molecules remain one of the most important therapeutic modalities in drug development. Our teams have decades of experience in the development of these cost-effective, often orally delivered, and stable modalities for any number of indications including oncology, cardiovascular, neurology, immunology, and rare diseases.

Biologics, which include any number of large molecules, such as recombinant proteins, monoclonal antibodies, ADCs, and gene/cell therapies, have become one of the most significant classes of drugs in modern medicine. Our scientists are experienced in the development of this important and ever-evolving area to exploit their high target specificity, ability to treat previously untreatable diseases, and offer long duration of action.

Nucleic acids, which are the building blocks of DNA and RNA, have become one of the most transformative therapeutic modalities in modern pharma. Unlike small molecules or biologics that interact with proteins, nucleic acid–based drugs can modulate gene expression directly, enabling entirely new ways to treat or even cure disease.

Our diverse experience spans chemically synthesized oligonucleotides (e.g., ASO, siRNA, aptamer, sgRNA, PMO/PPMO, etc.) as well as larger nucleic acid polymers produced by biological processes, such as in vitro transcription (e.g., mRNA, tRNA, circular RNA, etc.) or bacterial expression (e.g., plasmid DNA).

Push the boundaries of what’s possible in drug development with our forward-looking partnership to help navigate uncertainty. We apply diverse molecular experience with proven processes and advance technologies to advance your product toward clinical phases.

Our team specialized numerous carriers to safeguard your API from environmental influences while optimizing pathways to the targeted cell and tissue types. Some of these include virus like particles (VLPs), viral vectors, adeno-associated virus (AAV), lipid nanoparticles (LNPs), and antibody-drug conjugates (ADCs).